FIELD: medicine.
SUBSTANCE: disclosed is use of 2-(tetra-O-acetyl-β-D-glucopyranosyloxy)-3-ethyl-5,8-dihydroxy-1,4-naphthoquinone as a base of pharmaceutical compositions for treating Parkinson's disease.
EFFECT: invention provides the neuronal and macrophage cell protection against the toxic effect of rotenone neurotoxin, promotes reducing the formation of active forms of oxygen and restoring the mitochondrial membrane potential in developing Parkinson's disease.
1 cl, 4 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| 2-((1H-1,2,4-TRIAZO-3-YL)THIO)-3-METHYL-6-(PROP-1-EN-2-YL)CYCLOHEX-3-EN-1-OL AS AN ANTIPARKINSONIAN AGENT | 2022 |
|
RU2796729C1 |
| PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASE | 2012 |
|
RU2618412C2 |
| AGENT STIMULATING HUMAN LEUKAEMIA CELL APOPTOSIS (VERSIONS) | 2007 |
|
RU2372919C2 |
| COMPOSITION FOR TREATING OR PREVENTING NEURODEGENERATIVE DISORDERS | 2012 |
|
RU2699038C2 |
| DRUG PREPARATION FOR PARKINSON DISEASE | 2014 |
|
RU2545734C1 |
| ACETILIZED GLYCOSIDES OF 2,5- AND 2,8-DIHYDROXY-1,4-NAPHTHOQUINONES POSSESSING ANTIFUNGUS ACTIVITY | 0 |
|
SU1088346A1 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
| GENETIC NUCLEOTIDE SEQUENCES OF ARTIFICIALLY MODIFIED GDNF WITH DELETED pro-REGION, PRODUCT OF WHICH HAS IMPROVED PROPERTIES NEURAL INDUCTOR AND STIMULATOR OF FORMATION OF NEURAL PROCESSES, SUITABLE FOR THERAPY OF NEURAL INJURIES, ISCHEMIC STROKES AND NEURODEGENERATIVE DISEASES, EXPRESSION VECTOR, MODIFIED WITH GDNF | 2014 |
|
RU2595377C2 |
| COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | 2011 |
|
RU2745439C2 |
